



**SDI Review Form 1.6**

Journal Name:	<a href="#">Journal of Cancer and Tumor International</a>
Manuscript Number:	Ms_JCTI_63661
Title of the Manuscript:	<b>Hypofractionated radiotherapy using simultaneous integrated boost technique With Concurrent and Adjuvant Temozolomide for glioblastoma multiforme</b>
Type of the Article	<b>Review Article</b>

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/journal/10/editorial-policy> )

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ol style="list-style-type: none"> <li>1) Introduction needs to be elaborated. Kindly quote the advantages and disadvantages of hypofractionation with suitable references. All sentences should be adequately cited. Introduction should mention the lacunae in knowledge and what this study adds to the present knowledge.</li> <li>2) Mention the type of study in methods section.</li> <li>3) Kindly proof read the article for grammatical and punctuation errors.</li> <li>4) Discussion should be further divided into paragraphs so that it looks better</li> </ol>	
<b>Minor</b> REVISION comments	<ol style="list-style-type: none"> <li>1) Grammatical and punctuation errors present in introduction in line 1,2,3 and 6 should be corrected</li> <li>2) The line informed consent had been written should be written as informed consent was taken. Section 2.2 "patients was" should be written as patients were. The first sentence of 2<sup>nd</sup> paragraph of section 2.3.1 should be reframe</li> <li>3) Section 2.3.2 first line should be corrected.</li> <li>4) In results section kindly mention units for age.</li> <li>5) Discussion second line should quote reference.</li> <li>6) In line 29 second paragraph of discussion the word " the" is repeated twice.</li> <li>7) In line 35 second paragraph of discussion the word "dysfunction" should be corrected.</li> <li>8) Grammatical error in line 40 second paragraph of discussion</li> <li>9) 3<sup>rd</sup> paragraph first line of discussion published at should be written as published in</li> <li>10) 3<sup>rd</sup> paragraph last line of discussion can be deleted</li> </ol>	
<b>Optional/General</b> comments	<ol style="list-style-type: none"> <li>1) I suggest to exclude patients who are not administered temozolamide from the study population as this may lead to confounding bias.</li> <li>2) A flowchart to show patient selection is advisable.</li> </ol>	



[SDI Review Form 1.6](#)

**PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>Raghav Yelamanchi</b>
Department, University & Country	<b>Atal Bihari Vajpayee Institute of Medical Sciences, India</b>